drugset
drugset / Trial / NCT03129555

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

NCT03129555 ↗

Phase 4 Active not recruiting 5000 enrolled Herlev and Gentofte Hospital
RandomizedCrossoverSingle-blindTreatment

Summary

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.

Timeline

Start
2023-04-01
Primary completion
2027-03-31
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule — Oral
Comparator Dabigatran etexilate Unknown — Oral
Comparator Edoxaban Small molecule — Oral
Comparator Rivaroxaban Other / unclassified — Oral

Indications

pulmonary embolism venous thromboembolism